Bridgebio Pharma, Inc. declined 1.95% in after-hours trading, following the announcement that the company will host an investor webinar on September 10, 2025, featuring Dr. Rachel Gafni, who will provide an overview of autosomal dominant hypocalcemia type 1 (ADH1) and the Company’s Phase 3 clinical trial, CALIBRATE.
Comments
No comments yet